Breaking News Instant updates and real-time market news.

CERS

Cerus

$6.18

-0.13 (-2.06%)

, AIMT

Aimmune

$26.16

-0.04 (-0.15%)

16:06
10/09/18
10/09
16:06
10/09/18
16:06

Cerus appoints Eric Bjerkholt to the board

Cerus Corporation (CERS) announced the appointment of Eric Bjerkholt to its Board of Directors. Mr. Bjerkholt currently serves as the chief financial officer of Aimmune Therapeutics (AIMT), a San Francisco Bay Area biopharmaceutical company focused on the development of treatments to help protect people with food allergies. Mr. Bjerkholt brings over three decades of healthcare and biotech leadership experience to the Cerus Board, which has now been expanded to eight members.

CERS

Cerus

$6.18

-0.13 (-2.06%)

AIMT

Aimmune

$26.16

-0.04 (-0.15%)

  • 06

    Nov

CERS Cerus
$6.18

-0.13 (-2.06%)

07/20/18
CANT
07/20/18
NO CHANGE
Target $9
CANT
Overweight
Cerus price target raised to $9 from $7 at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou raised his price target for Cerus to $9 and reiterates an Overweight rating on the shares after hosting investor meetings with management. The analyst is now more confident that the company's recent momentum should continue. He believes Cerus has "various growth drivers for the next several years". The FDA is moving closer to providing final guidance for methods to reduce bacterial contamination in transfused platelets, and Cerus' pathogen-inactivation technology should be included, Bijou tells investors in a research note.
01/04/18
CANT
01/04/18
INITIATION
Target $5
CANT
Overweight
Cerus assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage of Cerus with an Overweight rating and $5 price target.
AIMT Aimmune
$26.16

-0.04 (-0.15%)

09/13/18
STFL
09/13/18
INITIATION
Target $33
STFL
Hold
Aimmune initiated with a Hold at Stifel
Stifel analyst Derek Archila initiated Aimmune with a Hold rating and a price target of $33. The analyst contends that its "AR101 is approvable", with a meaningful uptake in the newly created peanut allergy immunotherapy category, which he estimates to become a "$3B market opportunity". Archila further notes that AR101 could achieve 20%-40% market share at its peak, adding that he would recommend the stock at a price below $25 per share.
08/13/18
FBCO
08/13/18
NO CHANGE
Target $40
FBCO
Outperform
Aimmune price target lowered to $40 form $47 at Credit Suisse
Credit Suisse analyst Vamil Divan lowered his price target for Aimmune to $40 from $47, while reiterating an Outperform rating on the shares. In conjunction with earnings, the analyst has adjusted his expected sales ramp for AR101, while also increasing his assumptions around expenses that will be required to successfully commercialize the product.
06/12/18
JMPS
06/12/18
NO CHANGE
Target $40
JMPS
Outperform
JMP Securities continues to recommend Aimmune after Dallas named CEO
JMP Securities analyst Liisa Bayko continues to recommend Aimmune (AIMT) shares following the company's "not-so-unexpected announcement" of a new CEO. Stephen Dilly announced plans to retire last fall and the incoming CEO, Jayson Dallas, who was most recently EVP and Chief Commercial Officer of Ultragenyx Pharmaceutical (RARE), has a skillset and expertise that should prove useful ahead of a potential launch of AR101, Bayko tells investors. She thinks a 5x multiple on her estimated peak sales of about $1B for AR101 is "justifiable," noting that this is before considering Aimmune's pipeline for egg and walnut allergy. Bayko keeps an Outperform rating and $40 price target on Aimmune shares.
05/29/18
JMPS
05/29/18
NO CHANGE
JMPS
JMP says AnaptysBio weakness ahead of asthma read-out a buying opportunity
After Aimmune Therapeutics (AIMT) presented new results from its Phase 3 trial of AR101 in peanut allergy at a medical congress, JMP Securities analyst Konstantinos Aprilakis noted that shares of competitor AnaptysBio (ANAB) are off about 42% over the last three months. He remains a buyer of AnaptysBio on any weakness going into the top-line proof of concept data from the Phase 2a trial of ANB020 in eosinophilic asthma, which is expected in Q3. The analyst, who reminds investors that he assigns about $61/share for the eosinophilic asthma indication in his valuation of AnaptysBio, maintains an Outperform rating and $180 price target on AnaptysBio shares, which closed Friday at $77.90.

TODAY'S FREE FLY STORIES

CRON

Cronos Group

$22.45

0.22 (0.99%)

, MO

Altria Group

$50.38

-0.14 (-0.28%)

17:37
02/21/19
02/21
17:37
02/21/19
17:37
Hot Stocks
Cronos Group shareholders approve C$2.4B investment from Altria Group »

Cronos Group (CRON)…

CRON

Cronos Group

$22.45

0.22 (0.99%)

MO

Altria Group

$50.38

-0.14 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

BAH

Booz Allen

$53.64

-0.105 (-0.20%)

, GD

General Dynamics

$171.66

-2.78 (-1.59%)

17:36
02/21/19
02/21
17:36
02/21/19
17:36
Hot Stocks
Booz Allen, General Dynamics, Leidos and SAIC awarded DTRA contracts »

Booz Allen (BAH), General…

BAH

Booz Allen

$53.64

-0.105 (-0.20%)

GD

General Dynamics

$171.66

-2.78 (-1.59%)

LDOS

Leidos

$62.87

1.175 (1.90%)

SAIC

SAIC

$75.73

-0.75 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

INFN

Infinera

$4.87

-0.02 (-0.41%)

17:35
02/21/19
02/21
17:35
02/21/19
17:35
Earnings
Infinera reports Q4 EPS (25c), consensus (27c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

ECIFF

EDF

$0.00

(0.00%)

17:33
02/21/19
02/21
17:33
02/21/19
17:33
Downgrade
EDF rating change  »

EDF downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEE

Lee Enterprises

$2.69

0.075 (2.87%)

17:32
02/21/19
02/21
17:32
02/21/19
17:32
Hot Stocks
Lee Enterprises' TownNews acquires CMS business from GTxcel »

Lee Enterprises announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CENX

Century Aluminum

$9.30

0.12 (1.31%)

17:31
02/21/19
02/21
17:31
02/21/19
17:31
Earnings
Century Aluminum reports Q4 EPS (43c), consensus (53c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

EXEL

Exelixis

$21.22

(0.00%)

17:30
02/21/19
02/21
17:30
02/21/19
17:30
Initiation
Exelixis initiated  »

Exelixis initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPSN

Epsilon Energy

$0.00

(0.00%)

17:30
02/21/19
02/21
17:30
02/21/19
17:30
Hot Stocks
Epsilon Energy sees 2019 production growth of 27%-33% y/y »

The company anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$14.13

0.245 (1.76%)

17:29
02/21/19
02/21
17:29
02/21/19
17:29
Earnings
SSR Mining sees FY19 gold production 395,000 equivalent ounces »

At the Marigold mine,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ENPH

Enphase Energy

$7.37

0.13 (1.80%)

17:29
02/21/19
02/21
17:29
02/21/19
17:29
Hot Stocks
Park West Asset Management reports 5.4% passive stake in Enphase Energy »

Park West Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

EPSN

Epsilon Energy

$0.00

(0.00%)

17:29
02/21/19
02/21
17:29
02/21/19
17:29
Hot Stocks
Epsilon Energy board approves $20M-$25M capital budget for 2019 »

Epsilon Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$14.13

0.245 (1.76%)

17:28
02/21/19
02/21
17:28
02/21/19
17:28
Earnings
SSR Mining reports Q4 adjusted EPS 4c, two estimates 0c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BIIB

Biogen

$320.99

-14.02 (-4.18%)

17:28
02/21/19
02/21
17:28
02/21/19
17:28
Initiation
Biogen initiated  »

Biogen initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 28

    May

DBX

Dropbox

$25.58

0.1 (0.39%)

17:27
02/21/19
02/21
17:27
02/21/19
17:27
Earnings
Dropbox sees FY19 revenue $1.63B-$1.64B, consensus $1.6B »

Sees FY19 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

QNST

QuinStreet

$13.52

-0.26 (-1.89%)

17:26
02/21/19
02/21
17:26
02/21/19
17:26
Hot Stocks
Park West Asset Management reports 5.0% passive stake in QuinStreet »

Park West Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 27

    Mar

APPN

Appian

$38.73

0.41 (1.07%)

17:26
02/21/19
02/21
17:26
02/21/19
17:26
Earnings
Appian sees FY19 EPS (46c)-(42c), consensus (44c) »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 07

    Mar

WAB

Wabtec

$73.59

-1.425 (-1.90%)

, GT

Goodyear Tire

$19.19

-0.2 (-1.03%)

17:26
02/21/19
02/21
17:26
02/21/19
17:26
Hot Stocks
S&P announces changes to S&P 400, 500 indices »

Wabtec (WAB) will replace…

WAB

Wabtec

$73.59

-1.425 (-1.90%)

GT

Goodyear Tire

$19.19

-0.2 (-1.03%)

GE

General Electric

$10.03

-0.07 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

DBX

Dropbox

$25.58

0.1 (0.39%)

17:26
02/21/19
02/21
17:26
02/21/19
17:26
Earnings
Dropbox sees Q1 revenue $379M-$382M, consensus $377.03M »

Guidance taken from Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

EIDX

Eidos Therapeutics

$14.99

-0.64 (-4.09%)

17:25
02/21/19
02/21
17:25
02/21/19
17:25
Initiation
Eidos Therapeutics initiated  »

Eidos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

NOC

Northrop Grumman

$287.50

-0.73 (-0.25%)

17:25
02/21/19
02/21
17:25
02/21/19
17:25
Hot Stocks
Northrop Grumman Australia unit to continue work on F-35 program »

Northrop Grumman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

APPN

Appian

$38.73

0.41 (1.07%)

17:25
02/21/19
02/21
17:25
02/21/19
17:25
Earnings
Appian sees Q1 EPS (17c)-(16c), consensus (12c) »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 07

    Mar

APPN

Appian

$38.73

0.41 (1.07%)

17:22
02/21/19
02/21
17:22
02/21/19
17:22
Earnings
Appian reports Q4 EPS (22c), consensus (16c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 07

    Mar

PTGX

Protagonist Therapeutics

$7.32

0.16 (2.23%)

17:20
02/21/19
02/21
17:20
02/21/19
17:20
Initiation
Protagonist Therapeutics initiated  »

Protagonist Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GT

Goodyear Tire

$19.19

-0.2 (-1.03%)

, WAB

Wabtec

$73.59

-1.425 (-1.90%)

17:20
02/21/19
02/21
17:20
02/21/19
17:20
Hot Stocks
Breaking Hot Stocks news story on Goodyear Tire, Wabtec »

Goodyear Tire to replace…

GT

Goodyear Tire

$19.19

-0.2 (-1.03%)

WAB

Wabtec

$73.59

-1.425 (-1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

WAB

Wabtec

$73.59

-1.425 (-1.90%)

, GT

Goodyear Tire

$19.19

-0.2 (-1.03%)

17:19
02/21/19
02/21
17:19
02/21/19
17:19
Hot Stocks
Wabtec to replace Goodyear Tire in S&P 500 at open on 2/27 »

General Electric (GE) is…

WAB

Wabtec

$73.59

-1.425 (-1.90%)

GT

Goodyear Tire

$19.19

-0.2 (-1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.